Stay updated on VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Sign up to get notified when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.

Latest updates to the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page
- Check2 days agoChange DetectedRevision indicator updated from v3.4.1 to v3.4.2 appears in the page footer. No study data, sections, or functionality were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now shows Revision: v3.3.4 in the footer, and Revision: v3.3.3 was removed.SummaryDifference0.0%

- Check53 days agoChange DetectedLocations section added with state-level site listings (Florida, Georgia, Indiana, Kansas, Louisiana, Missouri, New York, North Carolina, Rhode Island, South Carolina, Texas, Utah). Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure element.SummaryDifference1%

- Check83 days agoChange DetectedMinor editorial updates: the Publications disclaimer was reworded from 'study results' to 'results of the study', and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check90 days agoChange DetectedThe government funding status banner warning about potential delays and operating status has been removed from the page.SummaryDifference0.3%

Stay in the know with updates to VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.